Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US12220387B2 · kind B2 · utility
0Cited by
18References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2022 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Sep 29, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.